Arthur C Theodore1, Chi-Hong Tseng2, Ning Li3, Robert M Elashoff2, Donald P Tashkin4. 1. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Boston University School of Medicine, Boston, MA. Electronic address: atheodor@bu.edu. 2. Department of Biomathematics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA. 3. Biostatistics Core, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. 4. Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.
Abstract
BACKGROUND: Cough is a significant symptom in patients with scleroderma interstitial lung disease (SSc-ILD), affecting 73% of the 158 patients enrolled in the Scleroderma Lung Study (SLS), a multicenter randomized trial of oral cyclophosphamide (CYC) vs placebo (PLA) in patients with active interstitial lung disease. METHODS: We examined the correlation of cough frequency and severity and phlegm production at baseline in 156 SLS participants with other baseline variables representing SSc-ILD disease activity and the cough response to 1 year of treatment with CYC vs PLA. RESULTS: Patients with cough at baseline had significantly lower diffusing capacity of the lung for carbon monoxide, dyspnea, the quality-of-life physical component summary, and the maximal fibrosis score on high-resolution CT imaging compared with those without cough at baseline. Cough severity and frequency correlated with FVC % predicted. After 12 months of treatment, cough frequency decreased in the CYC group compared with the PLA group and was significantly different from the PLA group at 18 months (6 months after discontinuation of CYC). However, the decreases in cough frequency did not correlate with the changes in FVC or diffusing capacity of the lung for carbon monoxide observed in the CYC group. Treatment-related improvements in cough frequency, as well as in FVC, were no longer apparent 12 months after discontinuation of CYC. CONCLUSIONS: Cough is a common symptom in SSc-ILD and correlates with the extent of fibrosis. Cough frequency decreases significantly in response to treatment with CYC but returns to baseline 1 year after withdrawal of treatment. Cough may be a symptom of ongoing fibrosis and an independent variable in assessing therapeutic response to CYC. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT000004563; URL: www.clinicaltrials.gov
RCT Entities:
BACKGROUND: Cough is a significant symptom in patients with scleroderma interstitial lung disease (SSc-ILD), affecting 73% of the 158 patients enrolled in the Scleroderma Lung Study (SLS), a multicenter randomized trial of oral cyclophosphamide (CYC) vs placebo (PLA) in patients with active interstitial lung disease. METHODS: We examined the correlation of cough frequency and severity and phlegm production at baseline in 156 SLSparticipants with other baseline variables representing SSc-ILD disease activity and the cough response to 1 year of treatment with CYC vs PLA. RESULTS:Patients with cough at baseline had significantly lower diffusing capacity of the lung for carbon monoxide, dyspnea, the quality-of-life physical component summary, and the maximal fibrosis score on high-resolution CT imaging compared with those without cough at baseline. Cough severity and frequency correlated with FVC % predicted. After 12 months of treatment, cough frequency decreased in the CYC group compared with the PLA group and was significantly different from the PLA group at 18 months (6 months after discontinuation of CYC). However, the decreases in cough frequency did not correlate with the changes in FVC or diffusing capacity of the lung for carbon monoxide observed in the CYC group. Treatment-related improvements in cough frequency, as well as in FVC, were no longer apparent 12 months after discontinuation of CYC. CONCLUSIONS: Cough is a common symptom in SSc-ILD and correlates with the extent of fibrosis. Cough frequency decreases significantly in response to treatment with CYC but returns to baseline 1 year after withdrawal of treatment. Cough may be a symptom of ongoing fibrosis and an independent variable in assessing therapeutic response to CYC. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT000004563; URL: www.clinicaltrials.gov
Authors: H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin Journal: Clin Exp Rheumatol Date: 2010-11-03 Impact factor: 4.473
Authors: Daniel E Furst; Chi-Hong Tseng; Philip J Clements; Charlie Strange; Donald P Tashkin; Michael D Roth; Dinesh Khanna; Ning Li; Robert Elashoff; Dean E Schraufnagel Journal: Am J Med Date: 2011-05 Impact factor: 4.965
Authors: Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li Journal: Am J Respir Crit Care Med Date: 2007-08-23 Impact factor: 21.405
Authors: Philip J Clements; Michael D Roth; Robert Elashoff; Donald P Tashkin; Jonathan Goldin; Richard M Silver; Mildred Sterz; James R Seibold; Dean Schraufnagel; Robert W Simms; Marcy Bolster; Robert A Wise; Virginia Steen; M D Mayes; Kari Connelly; Mark Metersky; Daniel E Furst Journal: Ann Rheum Dis Date: 2007-05-07 Impact factor: 19.103
Authors: Jonathan Goldin; Robert Elashoff; Hyun J Kim; Xaiohong Yan; David Lynch; Diane Strollo; Michael D Roth; Philip Clements; Daniel E Furst; Dinesh Khanna; Srainnapha Vasunilashorn; Gang Li; Donald P Tashkin Journal: Chest Date: 2009-11 Impact factor: 9.410
Authors: Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements Journal: Arthritis Rheum Date: 2007-05
Authors: Nicole S L Goh; Srihari Veeraraghavan; Sujal R Desai; Derek Cramer; David M Hansell; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells Journal: Arthritis Rheum Date: 2007-06
Authors: Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin Journal: Am J Respir Crit Care Med Date: 2007-09-27 Impact factor: 21.405
Authors: Jonathan G Goldin; David A Lynch; Diane C Strollo; Robert D Suh; Dean E Schraufnagel; Philip J Clements; Robert M Elashoff; Daniel E Furst; Sarinnapha Vasunilashorn; Michael F McNitt-Gray; Mathew S Brown; Michael D Roth; Donald P Tashkin Journal: Chest Date: 2008-07-18 Impact factor: 9.410
Authors: Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo Journal: Curr Respir Med Rev Date: 2015
Authors: Donald P Tashkin; Elizabeth R Volkmann; Chi-Hong Tseng; Michael D Roth; Dinesh Khanna; Daniel E Furst; Philip J Clements; Arthur Theodore; Suzanne Kafaja; Grace Hyun Kim; Jonathan Goldin; Edgar Ariolla; Robert M Elashoff Journal: Chest Date: 2016-12-22 Impact factor: 9.410
Authors: David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna Journal: Semin Arthritis Rheum Date: 2021-08-20 Impact factor: 5.431
Authors: Lesley Ann Saketkoo; Tracy Frech; Cecília Varjú; Robyn Domsic; Jessica Farrell; Jessica K Gordon; Carina Mihai; Nora Sandorfi; Lee Shapiro; Janet Poole; Elizabeth R Volkmann; Monika Lammi; Kendra McAnally; Helene Alexanderson; Henrik Pettersson; Faye Hant; Masataka Kuwana; Ami A Shah; Vanessa Smith; Vivien Hsu; Otylia Kowal-Bielecka; Shervin Assassi; Maurizio Cutolo; Cristiane Kayser; Victoria K Shanmugam; Madelon C Vonk; Kim Fligelstone; Nancy Baldwin; Kerri Connolly; Anneliese Ronnow; Beata Toth; Maureen Suave; Sue Farrington; Elana J Bernstein; Leslie J Crofford; László Czirják; Kelly Jensen; Monique Hinchclif; Marie Hudson; Matthew R Lammi; Jennifer Mansour; Nadia D Morgan; Fabian Mendoza; Mandana Nikpour; John Pauling; Gabriela Riemekasten; Anne-Marie Russell; Mary Beth Scholand; Elise Seigart; Tatiana Sofia Rodriguez-Reyna; Laura Hummers; Ulrich Walker; Virginia Steen Journal: Best Pract Res Clin Rheumatol Date: 2021-09-15 Impact factor: 4.991